

Toms Pascual

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1644072/tomas-pascual-publications-by-citations.pdf>
Version: 2024-04-04

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62 papers	1,220 citations	19 h-index	34 g-index
91 ext. papers	1,942 ext. citations	6 avg, IF	4.12 L-index

#	Paper	IF	Citations
62	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <i>Cancer Research</i> , 2017 , 77, 3540-3550	10.1	213
61	Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value. <i>Breast Cancer Research</i> , 2011 , 13,	8.3	78
60	Lobular carcinoma of the breast: outcome of 205 patients. <i>Breast Cancer Research</i> , 2011 , 13,	8.3	78
59	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 45	8.3	55
58	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 1	7.8	54
57	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2020 , 21, 33-43	21.7	52
56	The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. <i>Breast</i> , 2014 , 23, 201-8	3.6	51
55	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 46-54	9.7	48
54	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CeTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. <i>Annals of Oncology</i> , 2018 , 29, 170-177	10.3	45
53	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2018 , 67, 63-70	14.4	45
52	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. <i>Annals of Oncology</i> , 2018 , 29, 2121-2128	10.3	41
51	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer 2019 , 7, 90		40
50	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101965	14.4	39
49	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. <i>Annals of Oncology</i> , 2019 , 30, 921-926	10.3	38
48	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020 , 11, 385	17.4	36
47	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. <i>Breast</i> , 2017 , 34 Suppl 1, S19-S26	3.6	35
46	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , 2020 , 21, 1455-1464	21.7	20

45	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. <i>Oncologist</i> , 2019 , 24, 603-611	5.7	20
44	Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. <i>PLoS ONE</i> , 2017 , 12, e0180192	3.7	19
43	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 5820-5829	12.9	17
42	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. <i>BMC Medicine</i> , 2019 , 17, 8	11.4	15
41	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. <i>Oncologist</i> , 2019 , 24, 893-900	5.7	12
40	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. <i>Breast Cancer Research</i> , 2019 , 21, 108	8.3	11
39	Abstract PD3-03: SOLTI-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer 2019 ,		10
38	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <i>Oncotarget</i> , 2017 , 8, 21930-21937	3.3	10
37	Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases. <i>Ecancermedicalscience</i> , 2016 , 10, 632	2.7	10
36	mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
35	A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. <i>Oncologist</i> , 2019 , 24, e1024-e1033	5.7	8
34	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. <i>Npj Precision Oncology</i> , 2021 , 5, 23	9.8	5
33	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 638482	5.3	5
32	Distribution of the PAM50 breast cancer subtypes within each pathology-based group: a combined analysis of 15,339 patients across 29 studies. <i>Annals of Oncology</i> , 2017 , 28, v603	10.3	4
31	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. <i>Future Oncology</i> , 2020 , 16, 1801-1813	3.6	4
30	Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial 2018 ,		4
29	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 571-571	2.2	4
28	Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. <i>Frontiers in Oncology</i> , 2019 , 9, 1178	5.3	4

27	Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-6	3.6	4
26	Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?. <i>Cancer Treatment Reviews</i> , 2022 , 106, 102392	14.4	4
25	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 303	5.3	3
24	PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III	7.5	3
23	Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer 2018 ,		3
22	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.. <i>EBioMedicine</i> , 2022 , 75, 103801	8.8	3
21	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2021 , 23, 42	8.3	3
20	Gene expression profiles of breast cancer metastasis according to organ site. <i>Molecular Oncology</i> , 2021 ,	7.9	3
19	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021 , 27, 3116-3125	12.9	3
18	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021 , 69, 103451	8.8	3
17	Abstract P2-09-04: Association of intrinsic subtype and immune genes with pathological complete response in the OPTIHER-HEART phase II clinical trial following neoadjuvant trastuzumab/pertuzumab-based chemotherapy in HER2-positive breast cancer 2018 ,		2
16	Estrogen receptor in HER2-positive early breast cancer: Two different diseases?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 642-642	2.2	2
15	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1025-1025	2.2	2
14	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. <i>Frontiers in Oncology</i> , 2021 , 11, 744112	5.3	2
13	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6141-6148	12.9	2
12	Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3226-7	2.2	2
11	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. <i>Npj Breast Cancer</i> , 2021 , 7, 8	7.8	2
10	Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07). <i>European Journal of Cancer Care</i> , 2020 , 29, e13253	2.4	1

9	Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 575-575	2.2	1
8	Clinical activity and cardiac tolerability of metronomic non-pegylated liposomal doxorubicin in heavily pre-treated patients with metastatic breast cancer: A single institution experience.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e11570-e11570	2.2	1
7	Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis.. <i>Cancer Treatment Reviews</i> , 2022 , 104, 102352	14.4	0
6	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021 , 7, 145	7.8	0
5	Phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer for neurotoxicity characterization: An OncoSur Study Group study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1029-1029	2.2	
4	Circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22042-e22042	2.2	
3	Retrospective analysis of 132 patients with stage I seminoma: Observation versus adjuvant radiation or chemotherapy in a single institution.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15033-e15033	2.2	
2	Long-term outcomes of cisplatin-based chemotherapy in patients with stage II-III germ cell tumors: Center 30-year experience of a single center.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 338-338	2.2	
1	Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study. <i>Cancer Research</i> , 2022 , 82, PD8-03-PD8-03	10.1	